marathon pharmaceuticals

Showing 3 posts of 3 posts found.

fda2outsideweb

FDA approves first treatment for Duchenne muscular dystrophy

February 10, 2017
Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, FDA, marathon, marathon pharmaceuticals

The FDA has announced that it has approved Emflaza (deflazacort), developed by Marathon Pharmaceuticals. The treatment will arrive on the …

FDA accepts Marathon’s Duchenne drug for priority review

August 11, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, deflazacort, marathon, marathon pharmaceuticals

Marathon Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted and granted a priority review for …

trials

Marathon Pharma submits application for Duchenne muscular dystrophy drug to FDA

June 15, 2016
Research and Development, Sales and Marketing FDA, duchenne, marathon pharmaceuticals

Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …

Latest content